Spots Global Cancer Trial Database for metastatic rectal adenocarcinoma

Every month we try and update this database with for metastatic rectal adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer	NCT03992456	Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re...	Panitumumab Quality-of-Life... Questionnaire A... Regorafenib Trifluridine an...	18 Years -	Academic and Community Cancer Research United
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial	NCT03765736	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re...	Genetic Testing	18 Years -	Academic and Community Cancer Research United
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	NCT04362839	Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Ipilimumab Nivolumab Regorafenib	18 Years -	City of Hope Medical Center
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer	NCT03300544	Locally Advance... Metastatic Rect... Rectal Adenocar... Stage III Recta... Stage IIIA Rect... Stage IIIB Rect... Stage IIIC Rect... Stage IV Rectal... Stage IVA Recta... Stage IVB Recta...	Capecitabine Fluorouracil Leucovorin Oxaliplatin Radiation Thera... Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	NCT05308446	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	National Cancer Institute (NCI)
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	NCT04362839	Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Ipilimumab Nivolumab Regorafenib	18 Years -	City of Hope Medical Center
BRIANSTORM - Early Identification of Patients With Brain Metastases	NCT05185557	Metastatic Rect... Brain Metastase...		18 Years -	Aarhus University Hospital
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	NCT04017650	BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	M.D. Anderson Cancer Center
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer	NCT05130060	Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Micr... Metastatic Micr... Metastatic Rect... Microsatellite ... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color...	Colorectal Canc... Trifluridine an...	18 Years -	Mayo Clinic
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	NCT04017650	BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	M.D. Anderson Cancer Center
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer	NCT04044430	Metastatic Colo... Metastatic Colo... Metastatic Micr... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Binimetinib Encorafenib Nivolumab Questionnaire A...	18 Years -	University of California, San Francisco
Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer	NCT02874885	Locally Advance... Metastatic Rect... Rectosigmoid Ad... Recurrent Recta... Recurrent Recto... Stage III Recta... Stage IIIA Rect... Stage IIIB Rect... Stage IIIC Rect... Stage IV Rectal... Stage IVA Recta... Stage IVB Recta... Stage IVC Recta...	Biospecimen Col...	18 Years -	M.D. Anderson Cancer Center
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	NCT04017650	BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	M.D. Anderson Cancer Center
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial	NCT03765736	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re...	Genetic Testing	18 Years -	Academic and Community Cancer Research United
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study	NCT04109924	Advanced Colore... Metastatic Colo... Metastatic Rect... Recurrent Colon... Recurrent Color... Recurrent Recta... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IV Colon ... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re...	Irinotecan Bevacizumab Trifluridine an...	18 Years -	Roswell Park Cancer Institute
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	NCT05308446	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	National Cancer Institute (NCI)
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer	NCT03300544	Locally Advance... Metastatic Rect... Rectal Adenocar... Stage III Recta... Stage IIIA Rect... Stage IIIB Rect... Stage IIIC Rect... Stage IV Rectal... Stage IVA Recta... Stage IVB Recta...	Capecitabine Fluorouracil Leucovorin Oxaliplatin Radiation Thera... Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study	NCT05356897	Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal...	Trastuzumab Trifluridine an... Tucatinib	18 Years -	Academic and Community Cancer Research United
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	NCT04362839	Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Ipilimumab Nivolumab Regorafenib	18 Years -	City of Hope Medical Center
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer	NCT03592641	Colorectal Carc... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re...	Savolitinib	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: